



Malmö 5 December 2025

**PRESS RELEASE**

## **Aptahem receives patent protection in China for patent family 2**

Aptahem AB (publ) announces today that the company has received patent protection in China for patent family 2 from the Chinese Patent Office.

With the approval in China of patent application 2018800643106, the protection of the company's drug candidate Aptahem-1 within patent family 2 in China, Chinese Patent No. 111386121, is valid until the end of 2038.

### **For further information:**

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

E-mail: [ml@aptahem.com](mailto:ml@aptahem.com)

### **About Aptahem**

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Aptahem-1, is currently in early clinical phase. Aptahem-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit [www.aptahem.com](http://www.aptahem.com).